Altris AI Unveils Flagging System to Streamline OCT Data Search and Biomarker Detection

Altris AI has launched a new advanced flagging system that enhances the way eye care professionals manage and navigate large volumes of optical coherence tomography (OCT) data. Designed to support both clinical decision-making and research workflows, the system allows for real-time identification of retinal pathologies and biomarkers associated with over 70 ocular conditions.

OCT Data Filtering Across Historical Archives

The new functionality enables clinicians to filter and retrieve OCT scans based on specific biomarkers or pathologies, such as soft drusen, dry AMD, or subretinal fluid. The tool offers the ability to scan through extensive historical datasets, creating well-defined patient cohorts for diagnostic review, long-term follow-up, or clinical studies.

For example, retina specialists monitoring geographic atrophy (GA) can now exclude GA-related biomarkers within 1, 3, and 6 mm ETDRS zones, improving the detection of early-stage GA and supporting timely intervention before vision loss progresses.

Cross-Device Compatibility and Interoperability

Altris AI reports that the system is fully functional across datasets originating from multiple imaging platforms, ensuring broad compatibility and high-precision flagging, regardless of the OCT device used.

“Flags are a clinical shortcut,” said Maria Znamenska, MD, PhD, Chief Medical Officer at Altris AI. “Instead of manually searching through thousands of scans, you can now filter precisely for what you need—whether that’s subretinal fluid, GA progression, or early glaucoma indicators. It’s about making the data work for you.”

Key Capabilities for Clinical and Research Applications

The flagging system is engineered to support a range of clinical and operational goals. Eye care professionals can now:

       • Track high-risk biomarkers and set reminders for patient follow-up

       • Identify candidates for ongoing or upcoming clinical studies within minutes

       • Facilitate treatment adoption by isolating eligible patient profiles

       • Analyze rare or complex cases through customizable pathology and biomarker filters

“Flags make it possible to build patient cohorts in minutes,” Dr. Znamenska added. “Whether it’s for research or introducing a new therapy, you now have a reliable tool to search for the right patients efficiently. For example, the FDA has recently approved the first treatment for Macular Telangiectasia Type 2, so eye care specialists can now search through their whole patient database and find those who have this particular pathology in minutes to offer them a new treatment.”